Omzo vs bmiMD: Compounded GLP-1 Care and Pricing Compared
Quick verdict: Omzo centers on clinician-guided access to compounded semaglutide and tirzepatide with semaglutide starting at $179 and options to get branded prescriptions, while bmiMD focuses on compounded tirzepatide with multi-month pricing as low as $139 per month and free shipping. This comparison highlights five clear differences to help you decide between Omzo vs bmiMD.
Explore Omzo clinician-guided plans
Direct comparison: what each provider specializes in
Omzo promotes clinician-guided GLP-1 care offering personalized compounded semaglutide and tirzepatide and may also provide prescriptions for branded medications that you must fill separately. bmiMD emphasizes compounded tirzepatide subscriptions with four billing options and free subscription shipping. Both note that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
Five key differences between Omzo and bmiMD
1) Medication offerings and prescription handling
Omzo: Personalized compounded semaglutide and tirzepatide through a compounding pharmacy, and clinicians may write prescriptions for branded medications like Ozempic or Wegovy which Omzo does not sell or ship. bmiMD: Focused on compounded tirzepatide (GLP-1/GIP) prepared in state-licensed pharmacies and delivered on subscription.
2) Pricing structure and payment commitments
Omzo: Lists semaglutide starting at $179 and tirzepatide starting at $279, described as personalized and clinician-guided. bmiMD: Offers a tiered subscription model with month-to-month at $179, three-month at $159 per month, six-month at $149 per month, and 12-month at $139 per month; the lowest monthly price requires a longer commitment.
3) Shipping and subscription features
Omzo: Notes fast, discreet delivery and that medication costs are included in fees collected by Omzo, with the pharmacy paid by Omzo. bmiMD: Promotes free subscription shipping on every order and online refills and delivery; turnaround and delivery timing are highlighted in captured landing-page content.
4) Clinician access and program oversight
Omzo: Describes clinician-guided plans reviewed by licensed U.S. providers and that clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility. bmiMD: Highlights 24/7 clinician access and clinician-reviewed online treatment with confirmation checks every 3 to 6 months to stay within target strength tolerances.
5) Regulatory and quality notes
Both providers state that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Omzo additionally clarifies that compounded medications are prepared by state-licensed sterile compounding pharmacies and that they are produced in FDA-registered facilities but are not FDA-approved.
| Criteria | Omzo | bmiMD |
|---|---|---|
| Primary medications offered | Compounded semaglutide & tirzepatide; clinicians may prescribe branded meds | Compounded tirzepatide (GLP-1/GIP) |
| Starting price | Semaglutide starting at $179; tirzepatide starting at $279 | $179 month-to-month; $159/3-month; $149/6-month; $139/12-month |
| Shipping | Fast, discreet delivery; medication costs included in fees collected | Free subscription shipping on every order |
| Clinician access | Clinician-guided plans reviewed by licensed U.S. providers | 24/7 clinician access; clinician-reviewed online treatment |
| Regulatory note | Compounded meds are not FDA-approved; produced in FDA-registered facilities | Compounded meds are not FDA-approved; prepared in state-licensed pharmacies |
How these differences affect your choice
If you value direct access to semaglutide specifically and a clinician-guided program that may also provide prescriptions for branded drugs to be filled separately, Omzo documents that offering. If lower long-term monthly cost, free subscription shipping, and a subscription cadence with 24/7 clinician access are the priority, bmiMD documents multi-month pricing down to $139 per month with online refills.
Compare bmiMD subscription options
Check Omzo eligibility and pricing
Bottom line and final recommendation on Omzo vs bmiMD
Omzo vs bmiMD comes down to product focus and price structure. Omzo emphasizes clinician-guided, personalized compounded semaglutide and tirzepatide with semaglutide starting at $179 and the option for clinicians to write branded prescriptions. bmiMD emphasizes compounded tirzepatide delivered on subscription with tiered pricing as low as $139 per month and free shipping. Compounded medications from both providers are not FDA-approved; verify eligibility, total cost, renewal terms, and state availability before enrolling.
Choose Omzo if…
you want clinician-guided access to compounded semaglutide and tirzepatide, value plans reviewed by licensed U.S. providers, or may need a clinician to write a prescription for a branded medication to fill separately.
Choose bmiMD if…
you prefer a subscription model focused on compounded tirzepatide with multiple billing options, free subscription shipping, and lower long-term monthly equivalents down to $139 per month.